Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17501963 | 0.81 | MEN1 (0.49) | HTTMAPTMEN1KMT2ASYK | |
| SCHEMBL17521942 | 0.78 | MEN1 (0.46) | HTTMAPTMEN1KMT2ASYK | |
| SCHEMBL6049741 | 0.77 | HTT (0.59) | HTTMAPTMEN1KMT2ASYK | |
| SCHEMBL17495253 | 0.76 | HTT (0.56) | HTTMAPTMEN1KMT2ASYK | |
| SCHEMBL23497295 | 0.76 | MEN1 (0.47) | MEN1KMT2A | |
| SCHEMBL28513293 | 0.75 | HTT (0.54) | HTTMAPTMEN1KMT2ASYK | |
| Glycolic Acid SCHEMBL145941 | 0.75 | HTT (0.58) | HTTMAPTMEN1KMT2AFOLH1 | |
| SCHEMBL22829840 | 0.75 | HTT (0.47) | HTTMAPTSYKL3MBTL1LMNA | |
| SCHEMBL22829843 | 0.74 | HTT (0.47) | HTTMAPTMEN1KMT2ASYK | |
| SCHEMBL15486172 | 0.74 | NAALAD2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9919055-B2 | Sugar-linker-drug conjugates | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160045611-A1 | SUGAR-LINKER-DRUG CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-18 | — | — | US | disclosed |
| US-20160038615-A1 | SACCHARIDE CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045611-A1 | SUGAR-LINKER-DRUG CONJUGATES | FUT5, FUT6, B3GNT2 | HTT 3197/4885MAPT 2433/4885MEN1 3709/4885 |
| US-20160038615-A1 | SACCHARIDE CONJUGATES | BLM, DCLRE1A, MAN1B1 | HTT 1879/4885MAPT 4192/4885MEN1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.